- Home
- SGC vs PRQR Comparison
SGC vs PRQR Comparison
Compare SGC & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGC | PRQR |
|---|---|---|
| Founded | 1920 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.2M | 166.4M |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SGC | PRQR |
|---|---|---|
| Price | $10.12 | $1.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $17.33 | $7.67 |
| AVG Volume (30 Days) | 30.4K | ★ 298.4K |
| Earning Date | 06-15-2026 | 01-01-0001 |
| Dividend Yield | ★ 5.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $566,184,000.00 | N/A |
| Revenue This Year | $0.73 | N/A |
| Revenue Next Year | $3.38 | $18.45 |
| P/E Ratio | $22.33 | ★ N/A |
| Revenue Growth | ★ 0.09 | N/A |
| 52 Week Low | $8.30 | $1.08 |
| 52 Week High | $14.46 | $3.10 |
Technical Indicators
Market Signals| Indicator | SGC | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 49.14 | 58.70 |
| Support Level | $9.72 | $1.65 |
| Resistance Level | $10.48 | $2.27 |
| Average True Range (ATR) | 0.43 | 0.10 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 36.53 | 67.54 |
Price Performance
Historical ComparisonAbout SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.